JP6866043B2 - トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法 - Google Patents

トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法 Download PDF

Info

Publication number
JP6866043B2
JP6866043B2 JP2017526523A JP2017526523A JP6866043B2 JP 6866043 B2 JP6866043 B2 JP 6866043B2 JP 2017526523 A JP2017526523 A JP 2017526523A JP 2017526523 A JP2017526523 A JP 2017526523A JP 6866043 B2 JP6866043 B2 JP 6866043B2
Authority
JP
Japan
Prior art keywords
alkyl
acid
linear
branched
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017526523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535555A5 (enExample
JP2017535555A (ja
Inventor
マリニン，ウラジミール
パーキンス，ウォルター
ライファー，フランツィスカ
エム． コニーチェク，ドナ
エム． コニーチェク，ドナ
リ，ジーリー
プラウント，アダム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of JP2017535555A publication Critical patent/JP2017535555A/ja
Publication of JP2017535555A5 publication Critical patent/JP2017535555A5/ja
Application granted granted Critical
Publication of JP6866043B2 publication Critical patent/JP6866043B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017526523A 2014-11-18 2015-11-18 トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法 Active JP6866043B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081515P 2014-11-18 2014-11-18
US62/081,515 2014-11-18
PCT/US2015/061427 WO2016081658A1 (en) 2014-11-18 2015-11-18 Methods of manufacturing treprostinil and treprostinil derivative prodrugs

Publications (3)

Publication Number Publication Date
JP2017535555A JP2017535555A (ja) 2017-11-30
JP2017535555A5 JP2017535555A5 (enExample) 2018-12-27
JP6866043B2 true JP6866043B2 (ja) 2021-04-28

Family

ID=56014536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526523A Active JP6866043B2 (ja) 2014-11-18 2015-11-18 トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法

Country Status (7)

Country Link
US (5) US10343979B2 (enExample)
EP (2) EP3221291B1 (enExample)
JP (1) JP6866043B2 (enExample)
AU (1) AU2015349969B2 (enExample)
CA (1) CA2967385C (enExample)
ES (1) ES2873873T3 (enExample)
WO (1) WO2016081658A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4137127A1 (en) 2013-01-11 2023-02-22 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
KR102296259B1 (ko) 2013-10-25 2021-08-30 인스메드 인코포레이티드 프로스타사이클린 화합물, 조성물 및 이의 사용 방법
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
WO2017223400A1 (en) * 2016-06-24 2017-12-28 Insmed Incorporated Prostacyclin compounds and compositions for treating sarcoidosis
EP3515430A1 (en) * 2016-09-26 2019-07-31 United Therapeutics Corporation Treprostinil prodrugs
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
EP4017588A1 (en) 2019-08-23 2022-06-29 United Therapeutics Corporation Treprostinil prodrugs
US10781160B1 (en) * 2019-10-04 2020-09-22 Chirogate International Inc. Hexadecyl Treprostinil crystals and methods for preparation thereof
JP2023523557A (ja) 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル
CN116113415A (zh) 2020-06-09 2023-05-12 联合治疗公司 曲前列尼尔的富马酰基二酮哌啶前药
AU2021401921A1 (en) 2020-12-14 2023-07-06 United Therapeutics Corporation Methods of treating disease with treprostinil prodrugs
AU2022229367A1 (en) 2021-03-03 2023-09-14 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
KR20240141319A (ko) 2022-02-08 2024-09-26 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 일로프로스트 조합 치료 요법
AU2024208919A1 (en) 2023-01-19 2025-07-17 United Therapeutics Corporation Treprostinil analogs
WO2025101824A1 (en) 2023-11-09 2025-05-15 United Therapeutics Corporation Syntheses of compounds useful for producing treprostinil

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2947526A1 (de) 1978-11-29 1980-06-12 Ono Pharmaceutical Co Prostacyclin-analoge
US4668814A (en) 1984-03-08 1987-05-26 The Upjohn Company Interphenylene carbacyclin derivatives
JPS61289034A (ja) 1985-06-17 1986-12-19 Teijin Ltd イソカルバサイクリン類脂肪乳剤
US4837342A (en) 1986-02-28 1989-06-06 Sagami Chemical Research Center Prostacyclin analogue, and blood circulation improving agent and anti-ulcer composition containing it as active ingredient
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
GB9011588D0 (en) 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2056039A1 (en) 1991-01-22 1992-07-23 Philip L. Fuchs Carbacyclin analogs
US5190972A (en) 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
CA2312729C (en) 1997-11-14 2006-05-23 United Therapeutics Corporation Use of 9-deoxy-2', 9-.alpha.-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
KR20010033562A (ko) 1997-12-26 2001-04-25 오노다 마사요시 서방성 의약 조성물
AU5068999A (en) 1998-07-31 2000-02-21 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
US6265495B1 (en) * 1998-09-22 2001-07-24 Nippon Shokubai Co., Ltd. Method for production of esterified product
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
CA2359652A1 (en) 1999-03-31 2000-10-05 United Therapeutics Corporation Novel prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of peripheral vascular disease and pulmonaryhypertension
US6242482B1 (en) 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
CA2451432A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
US20030108512A1 (en) 2001-12-10 2003-06-12 Robert Shorr Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of cancer
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
AU2003258075A1 (en) 2002-08-06 2004-02-23 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases
US20050244503A1 (en) 2003-05-19 2005-11-03 Rabinow Barrett E Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents
ES2272914T3 (es) 2003-05-20 2007-05-01 Ethypharm Composicion farmaceutica oral de liberacion sostenida.
ES2622471T5 (es) 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
ES2331187T3 (es) 2003-12-16 2009-12-23 United Therapeutics Corporation Utilizacion de treprostinil para mejorar las funciones renales.
CA2549724C (en) 2003-12-16 2014-02-11 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
CN101287457B (zh) 2004-04-12 2011-11-16 联合治疗公司 Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
GB0416328D0 (en) 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
WO2006014930A2 (en) 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
WO2006043655A1 (ja) 2004-10-22 2006-04-27 Ono Pharmaceutical Co., Ltd. 吸入用医薬組成物
CA2631493A1 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
JP5797376B2 (ja) 2006-05-15 2015-10-21 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
EP2120961A1 (en) 2007-02-09 2009-11-25 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
ES2728785T3 (es) 2007-09-07 2019-10-28 United Therapeutics Corp Soluciones tampón con actividad bactericida selectiva contra las bacterias gramnegativas y métodos para usarlas
EP3287434A1 (en) 2007-12-17 2018-02-28 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin ®
CA2723540C (en) 2008-05-08 2016-01-05 United Therapeutics Corporation Treprostinil monohydrate
WO2009152160A1 (en) 2008-06-10 2009-12-17 Gilead Sciences, Inc. Inhaled carbaprostacyclin and prostacyclin prodrugs for the treatment of pulmonary arterial hypertension
US20110294815A1 (en) 2008-06-27 2011-12-01 Harbeson Scott L Prostacyclin analogs
WO2010039531A1 (en) 2008-09-23 2010-04-08 Resolvyx Pharmaceuticals, Inc. Therapeutic compounds
CN102164487A (zh) 2008-09-25 2011-08-24 阿拉迪姆公司 曲前列素的深肺部递送
WO2010100656A2 (en) 2009-02-20 2010-09-10 Micro Labs Limited Storage stable prostaglandin product
KR101544246B1 (ko) 2009-05-07 2015-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 유사체의 고체 제제
WO2011005505A2 (en) 2009-06-22 2011-01-13 Johnson Matthey Public Limited Company Method for the purification of prostaglandins
US20120270934A1 (en) 2009-07-03 2012-10-25 Concert Pharmaceuticals, Inc. Prostacyclin derivatives
ES2451790T3 (es) 2009-08-07 2014-03-28 Scipharm Sàrl Composición para el tratamiento de la fibrosis quística
EP2467170A4 (en) 2009-08-21 2013-05-29 Targeted Delivery Technologies Ltd vesicle
CN101669904B (zh) 2009-09-29 2011-06-22 北京中海康医药科技发展有限公司 一种依前列醇脂质纳米粒及制备方法
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2525830B1 (en) 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
JP5681276B2 (ja) 2010-03-15 2015-03-04 ユナイテッド セラピューティクス コーポレイション 肺高血圧症のための治療
CA3029711A1 (en) 2010-06-03 2011-12-08 United Therapeutics Corporation Treprostinil production
WO2011159693A2 (en) 2010-06-15 2011-12-22 United Therapeutics Corporation Oral treatment of digital ischemic lesions
US20120010159A1 (en) 2010-07-09 2012-01-12 United Therapeutics Corporation Combination therapies with cox-2 inhibitors and treprostinil
CA2710726C (en) 2010-07-22 2016-02-23 Alphora Research Inc. Synthesis of treprostinil and intermediates useful therein
WO2012107364A1 (en) 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
JP5780775B2 (ja) 2011-02-18 2015-09-16 株式会社Ｌｔｔバイオファーマ プロスタグランジンｉ２誘導体を含有するナノ粒子
WO2012118943A1 (en) 2011-03-02 2012-09-07 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
EP2687204B1 (en) 2011-03-14 2020-10-14 National University Corporation Hokkaido University Vector for pulmonary delivery, inducing agent, and uses
HK1198359A1 (en) 2011-08-12 2015-04-10 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
CA2843504C (en) 2011-08-12 2020-08-25 Ascendis Pharma A/S Protein carrier-linked prodrugs
HK1198629A1 (en) 2011-08-12 2015-05-22 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
EP3643306A3 (en) 2011-08-12 2020-08-26 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
HK1198358A1 (en) 2011-08-12 2015-04-10 Ascendis Pharma A/S Sustained release composition of prostacyclin
HK1198628A1 (en) 2011-08-12 2015-05-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
US8524939B2 (en) 2011-08-24 2013-09-03 Chirogate International Inc. Intermediates for the synthesis of benzindene prostaglandins and preparations thereof
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
ES2639823T3 (es) 2012-06-15 2017-10-30 Scipharm Sàrl Proceso para la preparación de treprostinilo y derivados del mismo
WO2014022376A2 (en) 2012-08-01 2014-02-06 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
CA2880808C (en) 2012-08-01 2023-01-24 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
AU2013351934B2 (en) 2012-11-30 2018-03-29 Insmed Incorporated Prostacylin compositions and methods for using the same
AU2014205557B2 (en) 2013-01-09 2017-08-10 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP4137127A1 (en) * 2013-01-11 2023-02-22 Corsair Pharma, Inc. Prodrugs of treprostinil
CA3212313A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
WO2014150203A1 (en) 2013-03-15 2014-09-25 United Therapeutics Corporation Salts of treprostinil
CA2908244C (en) 2013-03-25 2021-04-20 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
CN105407883A (zh) 2013-04-30 2016-03-16 联合治疗学有限公司 控释药物制剂
WO2014203278A2 (en) 2013-06-19 2014-12-24 Msn Laboratories Private Limited NOVEL PROCESS FOR THE PREPARATION OF (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-HEXAHYDRO-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[f]INDEN-5-YL]OXY]ACETIC ACID
JP6483714B2 (ja) 2013-10-11 2019-03-13 ローレンス エス． ジスマン， 噴霧乾燥製剤
KR102296259B1 (ko) * 2013-10-25 2021-08-30 인스메드 인코포레이티드 프로스타사이클린 화합물, 조성물 및 이의 사용 방법
WO2015138423A1 (en) 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
WO2015192030A1 (en) 2014-06-13 2015-12-17 United Therapeutics Corporation Treprostinil formulations
CA2964804C (en) 2014-10-20 2019-04-02 United Therapeutics Corporation Synthesis of intermediate for producing prostacyclin derivatives
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US20160318844A1 (en) 2015-04-29 2016-11-03 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
US10898494B2 (en) 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
WO2017223400A1 (en) 2016-06-24 2017-12-28 Insmed Incorporated Prostacyclin compounds and compositions for treating sarcoidosis
EP3515430A1 (en) 2016-09-26 2019-07-31 United Therapeutics Corporation Treprostinil prodrugs
EP3673895A1 (en) 2018-12-28 2020-07-01 Université Libre de Bruxelles Dry powder inhalation formulation and its use for the therapeutic treatment of lungs
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法

Also Published As

Publication number Publication date
ES2873873T3 (es) 2021-11-04
US11148997B2 (en) 2021-10-19
US20220135513A1 (en) 2022-05-05
AU2015349969A1 (en) 2017-05-25
US10343979B2 (en) 2019-07-09
EP3221291A4 (en) 2018-06-27
US20170320813A1 (en) 2017-11-09
HK1244783A1 (en) 2018-08-17
WO2016081658A1 (en) 2016-05-26
EP3221291A1 (en) 2017-09-27
CA2967385A1 (en) 2016-05-26
JP2017535555A (ja) 2017-11-30
EP3221291B1 (en) 2021-03-31
CA2967385C (en) 2023-05-16
AU2015349969B2 (en) 2020-02-06
US20190337888A1 (en) 2019-11-07
US20250162982A1 (en) 2025-05-22
US20230250051A1 (en) 2023-08-10
EP3904326A1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
JP6866043B2 (ja) トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法
AU2021408119B2 (en) Fibroblast activation protein inhibitor
CN109929001B (zh) 葡萄糖胺衍生物、其组合物及其医药用途
TW202241865A (zh) 成纖維細胞活化蛋白抑制劑
WO2010038765A1 (ja) 新規ｉ型天然セラミド誘導体およびその製造方法
HK1244783B (en) Methods of manufacturing treprostinil and treprostinil derivative prodrugs
JP4800558B2 (ja) 環状ペプチド誘導体
KR101931792B1 (ko) 심근 관류를 영상화하기 위한 조영제
US8841476B2 (en) Preparation of crystalline ezatiostat hydrochloride ansolvate form D
JP2004513949A (ja) 新規な４’−デメチル−４’−ｏ−置換−１−デオキシポドフィロトキシン誘導体及びその幾何異性体、その製造方法及びそれを含んでなる抗癌剤組成物
JP7458984B2 (ja) テトラヒドロイソキノリン系誘導体、その製造方法及び用途
JP4910695B2 (ja) 血栓造影剤
CN112442010A (zh) 一类前药化合物及其在治疗癌症方面的应用
JP3177777B2 (ja) Ｓ―ニトロソチオール誘導体
ES3048032A1 (es) N-(4-Ariloxi-3-hidroxibutan-2-il)alcanamidas con actividad antagonista adrenérgica beta-2 selectiva
HK40031655B (zh) 四氢异喹啉类衍生物及其制备方法和用途
HK40031655A (en) Tetrahydroisoquinoline derivative, preparation method therefor and uses thereof
JPS6133145A (ja) 脂肪酸誘導体及びその製造法
HK1197064A1 (en) Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210406

R150 Certificate of patent or registration of utility model

Ref document number: 6866043

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250